Helping clients better compete in an evolving health market and improve cost-efficiency and profitability
Significant opportunities exist for pharmaceutical and life science companies. Successful organizations must have the scientific, commercial, and operational capabilities necessary to thrive in an increasingly complex health care environment. Although this is an exciting—and unprecedented—time to deliver outcomes that create proven value for patients, a flurry of policy proposals, new regulations and investigations into drug pricing practices are changing the way medicines are bought and sold around the world. Alongside the drug pricing impact, workforce advancements are evolving how pharma companies operate. Adoption of advanced technologies like Artificial Intelligence (AI) and Robotic Process Automation (RPA) can help companies to divest non-core assets, reduce costs and improve legacy processes. Digital therapeutics are reshaping the landscape for new medicines, product reimbursement and regulatory oversight.
Pharmaceutical and Life Science companies face unprecedented challenges. And while there are more opportunities and resources available, many companies still struggle to deliver optimal outcomes. We work across the industry value chain - from Biotech to Big Pharma and from from CRO to Medical Device - to help our clients compete, optimize and thrive... from strategy through execution.
Karen C. Young
US Pharmaceutical and Life Sciences Leader, PwC US
US Health Industries Tax Leader, PwC US
Global Pharmaceutical and Life Sciences Advisory Leader, PwC US
Principal, Strategy&, PwC US
Pharmaceutical and Life Sciences Deals Leader, PwC US
US Pharmaceutical & Life Sciences Assurance Leader, PwC US
US Pharmaceutical and Life Sciences Risk Assurance Leader, PwC US